Once-Daily OROS ® Methylphenidate Is Safe and Well Tolerated in Adolescents With Attention-Deficit/Hyperactivity Disorder
- 1 June 2006
- journal article
- research article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 16 (3) , 351-356
Abstract
This 8-week, open-label extension of a double-blind study reports on safety data for 171 adolescents with attention-deficit/hyperactivity disorder (ADHD) who received once-daily OROS methylphenidate (MPH) (18-72 mg/day). Headache, anorexia, and insomnia were the most frequently reported treatment-related adverse events. The incidence of adverse events was not related to dose. OROS MPH was safe and well tolerated at doses up to 72 mg/day.Keywords
This publication has 21 references indexed in Scilit:
- Multisite Controlled Study of OROS Methylphenidate in the Treatment of Adolescents With Attention-Deficit/Hyperactivity DisorderArchives of Pediatrics & Adolescent Medicine, 2006
- Attention-Deficit/Hyperactivity Disorder: Increased Costs for Patients and Their FamiliesJournal of the American Academy of Child & Adolescent Psychiatry, 2003
- PSYCHIATRIC DIAGNOSIS IN PRESCHOOL CHILDRENJournal of the American Academy of Child & Adolescent Psychiatry, 2003
- Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and AdultsJournal of the American Academy of Child & Adolescent Psychiatry, 2002
- Clinical Practice Guideline: Treatment of the School-Aged Child With Attention-Deficit/Hyperactivity DisorderPediatrics, 2001
- Dose–response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD.Experimental and Clinical Psychopharmacology, 2001
- Age-Dependent Decline of Symptoms of Attention Deficit Hyperactivity Disorder: Impact of Remission Definition and Symptom TypeAmerican Journal of Psychiatry, 2000
- Are Stimulants Overprescribed? Treatment of ADHD in Four U.S. CommunitiesJournal of the American Academy of Child & Adolescent Psychiatry, 1999
- Stimulant MedicationsJournal of the American Academy of Child & Adolescent Psychiatry, 1999
- Persistence of hyperactivity symptoms from childhood to adolescence and associated outcomes.American Journal of Orthopsychiatry, 1987